List view / Grid view
The process of manufacturing a biotherapeutic drug entails numerous quality control measures to ensure safety and efficacy. The articles in this in-depth focus discuss higher order structure analysis and host cell protein contamination issues.
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
Our culture media are the reliable and convenient choice for aseptic process simulation and include Ready-to-use and Dehydrated Culture Media to meet the specific needs in the pharmaceutical industry.
Spray-dried lactose is widely used as a filler and binder in the pharmaceutical industry, but many adults are not able to digest lactose. Therefore, it is indispensable to provide alternatives to lactose-containing drugs in order to make them suitable for lactose intolerant patients.
The company has announced a recall of products which were intended to be sterile after a lack of sterility assurance.
A multi-company system to improve traceability of pharmaceutical products is newly supported by the FDA.
In this issue we explore reasons behind critical key drug shortages in the EU, whether viability methods effectively detect all viable organisms and how companies can future-proof their digital technologies ahead of Brexit. Also included are articles on higher order protein structure, FMD compliance and Raman spectroscopy.
Luxembourg and the Netherlands have been included in the mutual recognition agreement between the EU and the FDA in the US.
At PQE Group we foster innovation, efficiency and quality services for sustainable regulated compliance solutions.
The Parenteral Drug Association (PDA) is excited to host its 4th Annual European Meeting.
Decreased supply of anti-rabies vaccines (ARVs) in Delhi causes outbreak of the disease.
The global pharmaceutical intermediates market is likely to see year-on-year growth in 2019, by an estimated 3.6 percent rate.
Lubricants have a far more wide-reaching impact on the characteristics of the finished tablet than merely easing their means of production. A study was carried out to investigate precisely what those effects were.
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
Heritage has recalled two of its injectable treatments after microbial growths were found.
